The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis.
Ontology highlight
ABSTRACT: The appearance of new disease-modifying therapies in multiple sclerosis (MS) has revolutionized our ability to fight inflammatory relapses and has immensely improved patients' quality of life. Although remarkable, this achievement has not carried over into reducing long-term disability. In MS, clinical disability progression can continue relentlessly irrespective of acute inflammation. This "silent" disease progression is the main contributor to long-term clinical disability in MS and results from chronic inflammation, neurodegeneration, and repair failure. Investigating silent disease progression and its underlying mechanisms is a challenge. Standard MRI excels in depicting acute inflammation but lacks the pathophysiological lens required for a more targeted exploration of molecular-based
SUBMITTER: Ben-Shalom I
PROVIDER: S-EPMC8745199 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA